Previous close | 43.38 |
Open | 42.59 |
Bid | 44.13 x 200 |
Ask | 44.24 x 200 |
Day's range | 41.75 - 45.19 |
52-week range | 18.00 - 53.92 |
Volume | |
Avg. volume | 1,140,066 |
Market cap | 3.273B |
Beta (5Y monthly) | 0.82 |
PE ratio (TTM) | N/A |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
R&D Expenses: R&D expenses increased to $150.5 million in 2023, reflecting investment in clinical trials and drug development. Net Loss: Net loss widened to $325.1 million in 2023, with a loss per share of $5.15.
Chief Commercial Officer Bhavesh Ashar has executed a sale of 8,056 shares of SpringWorks Therapeutics Inc (NASDAQ:SWTX) on February 5, 2024, according to a recent SEC filing.
Daniel Pichl, Chief People Officer of SpringWorks Therapeutics Inc (NASDAQ:SWTX), executed a sale of 26,181 shares in the company on February 2, 2024, according to a recent SEC Filing.